Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NBIX
NEUROCRINE BIOSCIENCES, INC.
NASDAQ
$154.06
▼ DOWN 1.19% (-1.86)

KEY STATISTICS

Market Cap$15.49 B
52w High$186.12
52w Low$122.14
Dividend Yield—
Frequency—
P/E22.26
Volume812.95K
Shares Out.100.55M

COMPANY

LEADERSHIP

Kyle W. Gano
CHIEF EXECUTIVE
Kyle W. Gano

COMPENSATION 2026

Salary$698,217
Stock Awards$3,700,106
Incentive Plan Pay$0
All Other Comp.$50,223
Total$8,535,422

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 23, 1996
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
2,500

PRICE TARGET

Target High$230.00
Target Low$165.00
Target Median$206.00
Target Consensus$203.11

UPCOMING EARNINGS

DateOct 27, 2026
DayTuesday
Rev. Est.$1.04B
OCT
27
TUE

PRICE

$154.06 ▼ DOWN 1.19% (−$1.86)
$153$154$155$1569:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM154.06

About Neurocrine Biosciences, Inc.

https://www.neurocrine.com ↗

Neurocrine Biosciences develops and markets drugs for neurological, endocrine, and psychiatric disorders, including INGREZZA for tardive dyskinesia and treatments for Parkinson's, endometriosis, and uterine fibroids, with several clinical-stage ca...

INDUSTRY

Biotechnology

A PRODUCT NEUROCRINE BIOSCIENCES, INC. IS KNOWN FOR

INGREZZA® Sprinkle (valbenazine) capsules
INGREZZA® Sprinkle (valbenazine) capsules

INGREZZA® Sprinkle, FDA-approved in April 2024, is a new capsule formulation of Neurocrine Biosciences' flagship VMAT2 inhibitor, offering a convenient option for adults with tardive dyskinesia or Huntington's disease-related chorea.

COMPETITORS

COMPETITOR
BIIB COMPARE
IONS COMPARE
TEVA COMPARE
VRTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$789.9M $798.3M ▲$811M ▲$954.3M ▲
Collaboration Revenue$5M $7.2M ▲$3.5M ▼$4.7M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
606
LISTED HERE
26
RANKED BY POSITION SIZE
XMC.TO
0.43% · 3.5M
VTI
0.02% · 3.2M
MDY
0.43% · 736.6K
XMHQ
1.65% · 600.5K
VFLO
0.79% · 554.4K
FBT
2.67% · 511.2K
SZNE
5.91% · 415.3K
SCHM
0.29% · 278.2K
JGRO
0.30% · 195.5K
FMDE
0.27% · 146.3K
DFAC
0.04% · 142.7K
DSTL
0.64% · 86.9K
JHMM
0.20% · 78.3K
FLQM
0.67% · 68.0K
JSMD
0.97% · 67.0K
CSMD
1.62% · 50.3K
BBH
1.62% · 49.9K
CLSE
0.83% · 48.0K
QCEU.PA
2.46% · 47.6K
XDWH.L
0.17% · 45.1K
TMSL
0.19% · 37.8K
QGRO
0.24% · 31.9K
HMWD.L
0.02% · 30.2K
AVUS
0.03% · 25.2K
LABU
0.59% · 23.9K
PB
PBPH
0.34% · 22.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
74.58%
HOLDERS
1,075
TOP 12 OF 1,075 · RANKED BY POSITION SIZE
Blackrock Inc.
14.2M sh · $1.95B
Blackrock, Inc.
13.7M sh · $2.31B
Vanguard Group Inc
9.7M sh · $1.36B
Jpmorgan Chase & Co
6.4M sh · $1.09B
Dodge & Cox
5.6M sh · $941.22M
Aqr Capital Management LLC
4.9M sh · $650.66M
State Street Corp
4.4M sh · $739.13M
Janus Henderson Investors Us LLC
4.4M sh · $188.76M
Bb Biotech AG
3.4M sh · $296.61M
Two Sigma Investments, LP
3.1M sh · $403.2M
Price T Rowe Associates Inc /Md/
2.9M sh · $402.43M
Renaissance Technologies LLC
2.4M sh · $318.67M

RATINGS SNAPSHOT

Overall rating: A

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity3
Price To Earnings2
Price To Book2
Overall Score4

TRADES BY CONGRESS

HOUSE TRADES
Lisa McClain
Lisa McClain
Sale (Partial)
2025-06-17
 Michael McCaul
Michael McCaul
Sale
2024-11-19
 Ro Khanna
Ro Khanna
Sale
2023-02-10
 Gilbert Cisneros
Gilbert Cisneros
Purchase
2020-12-21

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Onyia Jude
Sale · 2.4K shares
2026-08-04
★
DIRECTOR
Norwalk Leslie V
Sale · 1.3K shares
2026-07-28
★
DIRECTOR
Norwalk Leslie V
Sale · 842 shares
2026-07-29
★
DIRECTOR
Norwalk Leslie V
Purchase · 842 shares
2026-07-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 9
OVERWEIGHT 4
OUTPERFORM 3
EQUAL WEIGHT 1
MARKET PERFORM 1
NEUTRAL 1
19 GRADES IN THE LAST 12 MONTHS
Morgan Stanley EQUAL WEIGHT Truist Securities BUY Wedbush OUTPERFORM Canaccord Genuity BUY TD Cowen BUY Cantor Fitzgerald OVERWEIGHT Citigroup BUY Guggenheim BUY

SECTORS PEERS

PEERPRICE
VTRS$16.34COMPARE
COO$71.17COMPARE
ICLR$170.02COMPARE
SNN$28.97COMPARE
ELAN$24.11COMPARE
TEM$64.04COMPARE
SMMT$13.73COMPARE
UHS$171.66COMPARE